KALA

Kala Pharmaceuticals Inc

KALA, USA

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

https://www.kalarx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KALA
stock
KALA

How Regulatory Changes Could Impact Morepen Laboratories Limiteds Business - Global Trade Effects & Explosive Growth Opportunities earlytimes.in

Read more →
KALA
stock
KALA

Kala Pharmaceuticals stock falls after $10 million share offering Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$1.5

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.55

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

87.29 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-30.23 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 55.53% of the total shares of Kala Pharmaceuticals Inc

1.

Baker Bros Advisors LP

(17.1185%)

since

2025/06/30

2.

Cormorant Asset Management, LLC

(8.5889%)

since

2025/06/30

3.

SR ONE CAPITAL MANAGEMENT, LP

(8.5306%)

since

2025/06/30

4.

Woodline Partners LP

(4.275%)

since

2025/06/30

5.

AIGH Capital Management, LLC

(4.2729%)

since

2025/06/30

6.

Vanguard Group Inc

(2.4266%)

since

2025/06/30

7.

ADAR1 Capital Management LLC

(2.134%)

since

2025/06/30

8.

UBS O'Connor LLC

(1.9734%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(1.6091%)

since

2025/07/31

10.

Geode Capital Management, LLC

(0.8028%)

since

2025/06/30

11.

Perceptive Advisors LLC

(0.7866%)

since

2025/06/30

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7636%)

since

2025/07/31

13.

Fidelity Extended Market Index

(0.4041%)

since

2025/07/31

14.

BlackRock Inc

(0.3042%)

since

2025/06/30

15.

Renaissance Technologies Corp

(0.2478%)

since

2025/06/30

16.

XTX Topco Ltd

(0.185%)

since

2025/06/30

17.

Fidelity Total Market Index

(0.1691%)

since

2025/07/31

18.

Northern Trust Corp

(0.1481%)

since

2025/06/30

19.

Extended Equity Market Fund K

(0.1276%)

since

2025/06/30

20.

Fidelity Series Total Market Index

(0.1007%)

since

2025/07/31

21.

Spartan Extended Market Index Pool F

(0.0908%)

since

2025/07/31

22.

NT Ext Equity Mkt Idx Fd - L

(0.0783%)

since

2025/06/30

23.

Northern Trust Extended Eq Market Idx

(0.0783%)

since

2025/06/30

24.

NT Ext Equity Mkt Idx Fd - NL

(0.0665%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0516%)

since

2025/06/30

26.

Spartan Total Market Index Pool G

(0.0472%)

since

2025/07/31

27.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0221%)

since

2025/06/30

28.

Tower Research Capital LLC

(0.0163%)

since

2025/06/30

29.

Covestor Ltd

(0.0162%)

since

2025/06/30

30.

Extended Equity Market Fund M

(0.0161%)

since

2025/06/30

31.

Morgan Stanley - Brokerage Accounts

(0.0138%)

since

2025/06/30

32.

Vanguard U.S. Eq Idx £ Acc

(0.0119%)

since

2025/07/31

33.

Fidelity Nasdaq Composite Index

(0.0099%)

since

2025/07/31

34.

Blackrock US Eq Mkt Fund CF

(0.0095%)

since

2025/06/30

35.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0089%)

since

2024/12/31

36.

U.S. Equity Market Fund F

(0.0082%)

since

2025/06/30

37.

State St US Extended Mkt Indx NL Cl C

(0.0061%)

since

2025/08/31

38.

Mccormack Advisors International

(0.0043%)

since

2025/06/30

39.

JPMorgan Chase & Co

(0.0034%)

since

2025/06/30

40.

Steward Partners Investment Advisory, LLC

(0.0017%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.07

EPS Estimate

-1.01

EPS Difference

-0.06

Surprise Percent

-5.9406%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(6)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.